Octreotide: an active agent in epithelial ovarian carcinoma?
Jones
Robert H
RH
Cancer Research UK Molecular Oncology Group, Department of Pathology and Microbiology, School of Medical Sciences, Bristol, UK. Rob.Jones@bristol.ac.uk
Reubi
Jean-Claude
JC
Millan
David
D
Vasey
Paul
P
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000032:analysis; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000150:complications; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017481:Receptors, Somatostatin / Q000032:analysis; D012075:Remission, Spontaneous; D014839:Vomiting / Q000188:drug therapy
D018931:Antineoplastic Agents, Hormonal; D018394:CA-125 Antigen; D017481:Receptors, Somatostatin; D015282:Octreotide